Zymeworks Authorizes Up To $200 Million In Buybacks — It Expects To Spend Less
The biotech plans approximately $140 million in purchases through 2028 while funding drug development and selective acquisitions.
Zymeworks, which develops antibody-based medicines and manages licensed healthcare assets, authorized up to $200 million in additional share buybacks Monday, according to its SEC filing. The company expects purchases of approximately $140 million through 2028, below the board's ceiling.
A Ceiling, Not A Spending Commitment
Zymeworks has completed its earlier 2026 program, which allowed up to $125 million in repurchases. The new authorization extends its effort to return capital by reducing the number of shares outstanding.
Management intends to begin the new purchases before year-end and can suspend or end the program without buying any shares. Zymeworks had approximately 68.7 million common shares outstanding on Wednesday.
For 2027, management plans to divide capital among drug research and development, selective acquisitions and repurchases. Zymeworks Chief Financial Officer Kristin Stafford said, "Maintaining flexibility around the pace of repurchases allows us to respond to market conditions and cash flow while prioritizing opportunities to create lasting value for shareholders."
Expected Payments Help Fund Purchases
Zymeworks plans to use existing financial resources and anticipated cash receipts to pay for the buybacks. Those receipts include $55 million in upfront fees when its Roche collaboration closes, which management expects before year-end pending antitrust clearance.
The company also expects a potential $100 million milestone payment tied to TRELEGY ELLIPTA in the first quarter of 2027. That payment depends on the product reaching the applicable sales threshold for 2026.
Royalties Alongside Antibody Research
Zymeworks' business combines licensed medicines with its own development programs for cancer, inflammation and autoimmune disease. Its main product, Ziihera, or zanidatamab, is approved for HER2-positive biliary tract cancer in the United States, China, Europe and Canada.
Jazz Pharmaceuticals and BeOne hold development and sales rights in different territories, generating milestone payments and royalties for Zymeworks. The company's portfolio also includes YUPELRI, or revefenacin, and pasritamig, a clinical-stage antibody Johnson & Johnson developed using Zymeworks technology.
Platform partners include Bristol-Myers Squibb, GSK, Daiichi Sankyo, Johnson & Johnson and Merck. Zymeworks earned $69.9 million in milestone payments and fees from these partners in 2025, while also pursuing its own early-stage cancer and autoimmune programs.
The planned buybacks run through 2028, with approximately $140 million in expected spending and discretion to change the pace as cash flows and market conditions change.
Sources
- 8-K Filing — Zymeworks Inc. (ZYME) — SEC EDGAR
- Exhibit a261116sharerepurchaseprog.htm — Zymeworks Inc. 8-K exhibit — SEC EDGAR
- Zymeworks Announces $200 Million Share Repurchase — globenewswire.com